Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 4, 2005, Pages 297-306

  Nieto, Yago ^a,b   Shpall, Elizabeth J ^a   Bearman, Scott I ^a   McSweeney, Peter A ^a   Cagnoni, Pablo J ^a   Matthes, Steve ^a   Gustafson, Dan ^a   Long, Michael ^a   Barón, Anna E ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Autologous transplantation; Docetaxel; High dose chemotherapy; Pharmacodynamics; Pharmacokinetics; Phase I trial

Indexed keywords

ACICLOVIR; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANALGESIC AGENT; CARBOPLATIN; CEFEPIME; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; FLUCONAZOLE; FUROSEMIDE; GABAPENTIN; GLUTAMINE; LEVOFLOXACIN; MELPHALAN; NEOSTIGMINE; ONDANSETRON; PROCHLORPERAZINE; PYRIDOXINE; VANCOMYCIN; XIPAMIDE;

ACNE CYSTICA; ACUTE HEPATITIS; ADENOCARCINOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CRYOTHERAPY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FECES INCONTINENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HAND FOOT SYNDROME; HODGKIN DISEASE; HUMAN; ILEUS; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; LIVER NECROSIS; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHODGKIN LYMPHOMA; ONYCHOLYSIS; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; SARCOMA; SCHOOL CHILD; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; TREATMENT FAILURE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; TAXOIDS;

EID: 20144389655     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.01.002     Document Type: Article

References (67)

1. J.H. Doroshow T. Synold Pharmacological basis for high-dose chemotherapy. In: K.G. Blume S.J. Forman F.R. Appelbaum, eds. Thomas' Hematopoietic Cell Transplantation 3rd ed 2004 Blackwell Science Inc Malden, MA 130-157
2. S. Stemmer P.J. Cagnoni E.J. et al. Shpall High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial J Clin Oncol 14 1996 1463-1472
3. L.T. Vahdat K. Papadopoulos C. Balmaceda et al. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer Clin Cancer Res 4 1998 1689-1695
4. W.W. Hu G.D. Long K.E. Stockerl-Goldstein et al. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer Clin Cancer Res 5 1999 3411-3418
5. G. Somlo J.H. Doroshow T. Synold et al. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: Toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome Br J Cancer 84 2001 1591-1598
6. I. Ringle S.B. Horwitz Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol J Natl Cancer Inst 83 1991 288-291
7. J.F. Riou A. Naudin F. Lavelle Effects of Taxotere on murine and human tumor cell lines Biochem Biophys Res Commun 187 1992 164-170
8. M.C. Bissery Preclinical pharmacology of docetaxel Eur J Cancer 31A suppl 4 1995 S1-S6
9. R.S. Herbst F.R. Khuri Mode of action of docetaxel - a basis for combination with novel anticancer agents Cancer Treat Rev 29 2003 407-415
10. S. Chan K. Friedrichs D. Noel et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group J Clin Oncol 17 1999 2341-2354
11. P. Ravdin J. Erban B. Overmoyer et al. Phase III comparison of taxotere and paclitaxel in patients with metastatic breast cancer (TAX 311) Eur J Cancer 5 suppl 1 2003 32
12. J.M. Nabholtz H.J. Senn W.R. Bezwoda et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group J Clin Oncol 7 1999 1413-1424
13. J.M. Nabholtz C. Falkson D. Campos et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial J Clin Oncol 21 2003 968-975
14. J.M. Nabholtz T. Pienkowski J. Mackey et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study abstr 141 Proc Am Soc Clin Oncol 21 2002 36a
15. P. Francis J. Schneider L. Hann et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer J Clin Oncol 12 1994 2301-2308
16. C.F. Verschraegen T. Sittisomwong A.P. Kudelka et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J Clin Oncol 18 2000 2733-2739
17. S.B. Kaye P.A. Vasey Docetaxel in ovarian cancer: Phase III perspectives and future development Semin Oncol 29 3 suppl 12 2002 22-27
18. N. Katsumata R. Tsunematsu K. Tanaka et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese cooperative study Ann Oncol 11 1999 1531-1536
19. F.A. Shepherd F.V. Fossella T. Lynch et al. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials Semin Oncol 28 1 suppl 2 2001 4-9
20. M.C. Bissery G. Nohynek G.J. Sanderink F. Lavelle Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience Anticancer Drugs 6 1995 339-355
21. A.R. Hanauske D. Degen S.G. Hilsenbeck et al. Effects of Taxotere and Taxol in vitro colony formation of freshly explanted human tumor cells Anticancer Drugs 3 1992 121-124
22. P. Garcia D. Braguer G. Carkes et al. Comparative effects of taxol and taxotere on two different human carcinoma cell lines Cancer Chemother Pharmacol 34 1994 335-343
23. I. Adachi T. Watanabe S. Takashima et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer Br J Cancer 73 1996 210-216
24. T. Taguchi S. Mori R. Abe et al. Late phase II clinical trial study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer Jpn J Cancer Chemother 21 1994 2625-2632
25. 2 as second line chemotherapy in advanced breast cancer [abstr 327] Breast Cancer Res Treat 76 suppl 1 2002 S88
26. J.E. Cortes R. Pazdur Docetaxel J Clin Oncol 13 1995 2643-2655
27. M.S. Aapro Docetaxel (Taxotere): A highly active taxoid with manageable toxicity Semin Oncol 22 2 suppl 4 1995 1-2
28. A.H. Calvert D.R. Newell M.E. Gore Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared with cisplatin? Semin Oncol 19 1 suppl 2 1992 155-163
29. B.L. Samuels J.D. Bitran High-dose intravenous melphalan: A review J Clin Oncol 13 1995 1786-1799
30. T.C. Shea M. Flaherty A. Elias et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support J Clin Oncol 7 1989 651-661
31. M.C. Bissery P. Vrignaud F. Lavelle Preclinical profile of docetaxel (taxotere): Efficacy as a single agent and in combination Semin Oncol 22 6 suppl 13 1995 3-16
32. J. Crown M. Pegram Platinum-taxane combinations in metastatic breast cancer: An evolving role in the era of molecularly targeted therapy Breast Cancer Res Treat 79 suppl 1 2003 S11-S18
33. M.D. Pegram G.E. Konecny C. O'Callaghan et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 2004 739-749
34. R. Bruno A. Riva D. Hille et al. Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials Am J Health Syst Pharm 54 suppl 2 1997 S16-S19
35. C. Dumontet A. Sonnet Y. Bastion et al. Prevention of high dose L-PAM induced mucositis by cryotherapy Bone Marrow Transplant 14 1994 492-494
36. G. Meloni S. Capria A. Proia et al. Ice pops to prevent melphalan-induced stomatitis Lancet 347 1996 1691-1692
37. P.M. Anderson G. Schroeder K.M. Skubitz Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy Cancer 83 1998 1433-1439
38. P.M. Anderson N.K.C. Ramsay X.O. Shu et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation Bone Marrow Transplant 22 1998 339-344
39. M.B. Cockerham B.B. Weinberger S.B. Lerchie Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation Ann Pharmacother 34 2000 300-303
40. S.J. Vukelja W.J. Baker H.A. Burris et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere J Natl Cancer Inst 85 1993 1432-1433
41. Avaiable at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
42. P. Therasse S.G. Arbuck E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205-216
43. B.D. Cheson S.J. Horning B. Coiffier et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244-1253
44. V. Chaudry E.K. Rowinsky S.E. Sartorius et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies Ann Neurol 35 1994 304-311
45. R.J. Ponec M.D. Saunders M.B. Kimmey Neostigmine for the treatment of acute colonic pseudo-obstruction N Engl J Med 341 1999 137-141
46. O. Correia C. Azevedo E. Pinto Ferreira et al. Nail changes secondary to docetaxel (Taxotere) Dermatology 198 1999 288-290
47. A.M. Minisini A. Tosti A.F. Sobrero et al. Taxane-induced nail changes: incidence, clinical presentation and outcome Ann Oncol 14 2003 333-337
48. B. Esmaeli L. Hidaji R.B. Adinin et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy Cancer 98 2003 504-507
49. M. Aapro R. Bruno Early clinical studies with docetaxel. Docetaxel Investigators Group Eur J Cancer 31A suppl 4 1995 S7-S10
50. N.K. Ibrahim A.A. Sahin R.A. Dubrow et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer Lancet 355 2000 281-283
51. C. Langer-Nitsche H.-J. Lück M. Heilmann Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer Acta Oncol 8 2000 1001
52. B. Greenbaum-Lefkoe J.G. Rosenstock J.B. Belasco et al. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan Cancer 55 1985 44-46
53. A. Brufsky J. Lebish C. Shanahan et al. Phase II trials of carboplatin/ docetaxel and carboplatin/docetaxel/trastuzumab as first line therapy for metastatic breast cancer [abstract] Breast Cancer Res Treat 62 2000 81
54. M.D. Pegram T. Pienkowski D.W. Northfelt et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 2004 759-769
55. A.M. Davies P.N. Lara Jr P.C. Mack D.R. Gandara Docetaxel in non-small cell lung cancer: A review Expert Opin Pharmacother 4 2003 553-565
56. J.C. Trent V. Valero D.J. Booser et al. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer Clin Cancer Res 9 2003 2426-2434
57. P.A. Vasey H. Roché D. Bisset et al. Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 2002 1072-1078
58. D.R. Budman G.R. Petroni J.L. Johnson et al. Phase II trial of docetaxel in non-Hodgkin's lymphomas: A study of the Cancer and Leukemia Group B J Clin Oncol 15 1997 3275-3279
59. J.M. Zekri R.E. Hough J.M. Davies et al. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma Br J Cancer 88 2003 1335-1338
60. A. Goncalves F. Viret J. Ciccolini et al. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors Clin Cancer Res 9 2003 102-108
61. L. Gianni C.M. Kearns A. Giani et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 1995 180-190
62. 2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer Cancer Chemother Pharmacol 47 2001 45-50
63. N.L. Seibel S.M. Blaney M. O'Brien et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: A collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial Clin Cancer Res 5 1999 733-737
64. P.L. Mitchell R. Basser M. Chipman et al. A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours Ann Oncol 14 2003 788-794
65. H.M. Prince D. Rischin G.C. Toner et al. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study Bone Marrow Transplant 26 2000 955-961
66. M.D. Pegram G.E. Konecny C. O'Callaghan M. Beryt R. Pietras D.J. Slamon Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 2004 739-749
67. C.J. Sweeney K.D. Miller S.E. Sissons et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 2001 3369-3372